Alamar Biosciences sharespopped around 30% on their first day of trading, as the disease detection and analysis company eyes regulatory approval.
What's next: Proceeds will fund a diagnostic version of Alamar's platform, which it plans to submit to the FDA next year for approval, president Tod White says.
